ULK1 Inhibition as a Targeted Therapeutic Strategy for FLT3-ITD-mutated Acute Myeloid Leukemia by 김진석 et al.
RESEARCH Open Access
ULK1 inhibition as a targeted therapeutic
strategy for FLT3-ITD-mutated acute
myeloid leukemia
Doh Yu Hwang1, Ju-In Eom2, Ji Eun Jang1, Hoi-Kyung Jeung2, Haerim Chung1, Jin Seok Kim1,
June-Won Cheong1 and Yoo Hong Min1*
Abstract
Background: In acute myeloid leukemia (AML), internal tandem duplication mutations in the FLT3 tyrosine kinase
receptor (FLT3-ITD) are associated with a dismal outcome. Although uncoordinated 51-like kinase 1 (ULK1), which
plays a central role in the autophagy pathway, has emerged as a novel therapeutic target for various cancers, its
role in FLT3-ITD AML remains elusive. In this study, we evaluated the effects of ULK1 inhibition on leukemia cell
death in FLT3-ITD AML.
Method: We evaluated ULK1 expression and the levels of apoptosis and autophagy following ULK1 inhibition in
FLT3-ITD AML cell lines and investigated the mechanism underlying apoptosis induced by ULK1 inhibition.
Statistical analysis was performed using GraphPad Prism 4.0 (GraphPad Software Inc).
Results: FLT3-ITD AML cells showed significantly higher ULK1 expression than FLT3-wild-type (WT) AML cells. Two
ULK1 inhibitors, MRT 68921 and SBI-0206965, induced apoptosis in FLT3-ITD AML cells, with relatively minimal
effects on FLT3-WT AML cells and normal CD34-positive cells. Apoptosis induction by ULK1 inhibition was
associated with caspase pathway activation. Interestingly, ULK1 inhibition paradoxically also induced autophagy,
showing synergistic interaction with autophagy inhibitors. Hence, autophagy may act as a prosurvival mechanism in
FLT3-ITD AML cells. FLT3-ITD protein degradation and inhibition of the ERK, AKT, and STAT5 pathways were also
observed in FLT3-ITD AML cells following treatment with ULK1 inhibitors.
Conclusion: ULK1 is a viable drug target and ULK1 inhibition may represent a promising therapeutic strategy
against FLT3-ITD AML.
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Background
FMS-like tyrosine kinase 3 internal tandem duplication
(FLT3-ITD)-mutated acute myeloid leukemia (AML) ac-
counts for up to 30% of adult AML cases, and the prog-
nosis of patients with FLT3-ITD-mutated AML is
extremely dismal owing to the high relapse rate after
chemotherapy and allogeneic stem cell transplantation [1].
Activating ITD mutations in FLT3 increases cell prolifera-
tion and survival, while blocking cellular differentiation
through the constitutive activation of canonical pathways
such as MAPK/ERK, PI3K/AKT, and STAT5; these mech-
anisms, together with other recurrent molecular abnor-
malities, are implicated in AML induction [2].
Several FLT3 tyrosine kinase inhibitors (TKIs) have
been developed to target the aberrantly activated FLT3
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receptor and to suppress constitutive tyrosine phosphor-
ylation in FLT3-ITD AML [3, 4]. A recent phase III ran-
domized study (RATIFY) demonstrated the survival
benefit of a combination of chemotherapy with FLT3
TKIs, leading to the approval of the FLT3 inhibitor mid-
ostaurin by the US Food and Drug Administration [5].
However, therapeutic responses to the currently avail-
able FLT3 TKIs, if any, are short-lived and followed by
early relapse in nearly all cases [4, 6, 7]; accordingly, the
development of resistance to these TKIs impedes their
therapeutic efficacy. Secondary mutations in the FLT3-
TK domain have been demonstrated as one of the mech-
anisms underlying this resistance [6]. Multiple FLT3-TK
domain mutations have been identified in therapy-
resistant patients and cell lines [3, 6]. Therefore, the de-
velopment of inhibitors to block each of these mutations
would require a major effort [3, 7]. More recently, muta-
tional analysis of samples from patients who had re-
lapsed after FLT3-TKI treatment, as well as data from
preclinical studies suggest that a cellular adaptive mech-
anism involving the activation of signaling pathways also
plays a role in the FLT3-TKI resistance pathway [8],
however, these pathways remain poorly elucidated. In
addition, the inability of FLT3 TKIs to eliminate
leukemia stem cells also contributes to treatment failure.
Therefore, novel FLT3-ITD-targeted therapeutic strat-
egies are necessary.
Autophagy is a cell-protective and degradative process
that recycles damaged and long-lived cellular compo-
nents [9]. Autophagy has opposing roles in cancers, de-
pending on the context, oncogenesis, biological features,
treatment, and progression [10–12]. In certain cases, au-
tophagy acts primarily as a tumor-suppressive mechan-
ism by maintaining genomic integrity and preventing
proliferation and inflammation [12]. Recent evidence
suggests that autophagy contributes to cancer initiation
and progression, as well as the development of resistance
to treatment [10, 12–14]. The dependence of the sur-
vival of numerous tumors on autophagy suggests that
the inhibition of autophagy represents a therapeutic
strategy against cancer that is broadly applicable across
various tumor types [15–17]. Autophagy may also have
context-specific roles in different types of AML, depend-
ing on the clonal origin, oncogenic drivers, and state of
leukemia expansion [18]. Autophagy is frequently found
to be reduced in human AML blasts, and the loss of key
autophagy genes has been shown to lead to leukemia initi-
ation and progression in a mouse model. Disruption of au-
tophagy and downregulation of autophagy-related genes
are reportedly involved in the initiation and progression of
AML. In contrast, recent studies have revealed that
leukemic blasts and leukemia stem cells can utilize autoph-
agy to respond to the specific energy demands during accel-
erated proliferation, and to counteract chemotherapeutic
stress [19, 20]. These mechanisms may be employed to en-
hance the sensitivity of chemotherapeutic agents targeting
leukemia cells. Furthermore, autophagy represents an at-
tractive therapeutic target for various cancers, especially for
autophagy-addicted tumors [15–17, 21]. Accordingly, au-
tophagy inactivation by pharmacological inhibition or
knockout of essential autophagy-related genes sensitizes
specific subsets of AML cells to chemotherapies and small-
molecule inhibitors, reduces the proportion of functional
leukemia-initiating cells, and extends patient survival [19].
To date, most clinical efforts have focused on the use of
general autophagy inhibitors, including chloroquine, hydro-
xychloroquine, and bafilomycin A1, either as a single agent
or in combination with other anti-cancer drugs [14]. How-
ever, the development of potent and selective autophagy in-
hibitors is difficult, in part because most core autophagic
proteins used in small-molecule inhibitor screening tech-
niques function far downstream in the pathway and are not
readily druggable [22, 23]. A major challenge related to the
use of autophagy-targeting drugs is their lack of potent and
selective activity [23].
Among the ATG proteins that mediate all steps of au-
tophagy flux, uncoordinated 51-like kinase 1 (ULK1) has
serine/threonine protein kinase activity and is consid-
ered a key protein in the regulation of autophagy initi-
ation [24, 25]. ULK1 forms a stable complex with
ATG13, FIP200, and ATG101 to regulate the recruit-
ment of the VPS34 complex, which consists of VPS34,
beclin-1, and ATG14L [25]. In addition, ULK1 acts in
later stages of the autophagy pathway, including autop-
hagosome maturation. ULK1 undergoes complex post-
translational modifications, including mammalian target
of rapamycin complex 1 (mTORC1) and AMP-activated
protein kinase (AMPK) [26], depending on the cellular
conditions. ULK1 has been shown to promote cell sur-
vival in several cancers [27]. Overexpression of ULK1 is
negatively correlated with prognosis in various cancers,
including colorectal cancer, breast cancer, human naso-
pharyngeal carcinoma, and esophageal squamous cell
carcinoma [28].
ULK1 is considered a promising target for autophagy
inhibition because of its central role in pathway activa-
tion, druggable nature, and apparent selectivity for au-
tophagy over other cellular functions [29]. Several small-
molecule inhibitors of ULK1 have been recently re-
ported. Although a second mammalian ATG1 ortholog,
ULK2, also promotes autophagy, the loss of ULK1 alone
is sufficient to abrogate autophagy in many cell types,
underscoring its particularly important role. The crystal
structures of ULK1 have provided insights into the drug-
gable pockets of kinase [30], leading to the development
of several inhibitors, including SBI-0206965, MRT
68921, and recently, ULK-101 [27]. Although they are
still in the early stages of development, these agents
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provide new opportunities for the pharmacologic inhib-
ition of autophagy that can potentially be translated to
the clinic.
In this study, we evaluated the effects of the ULK1 in-
hibitors MRT 68921 and SBI-0206965 on apoptosis, and
the potential of therapeutic strategies involving ULK1
targeting in FLT3-ITD AML cells. In particular, we
aimed to elucidate the mechanisms underlying the ef-
fects of these ULK1 inhibitors on FLT3-ITD AML cell
death.
Materials and methods
Cell lines and culture
The human FLT3-ITD-mutated myeloid leukemia cell
lines MV4;11 and MOLM-13 and the FLT3-ITD-
negative myeloid leukemia cell lines HL60 and U937,
were purchased from the American Type Culture Col-
lection (Rockville, MD, USA). MV4;11 and MOLM-13
cells were grown in RPMI (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS).
HL60 and U937 cells were cultured in RPMI-1640 (Invi-
trogen) supplemented with 10% FBS. Cultures were in-
cubated in a 5% CO2 humidified incubator at 37 °C.
Patients and AML cell isolation
This study adhered to the tenets of the Declaration of
Helsinki and was approved by the institutional review of
board of Severance Hospital (Seoul, Korea). Study partic-
ipants provided written informed consent, and all patient
and healthy donor samples were coded and linked an-
onymously. Sample identification was made possible by
using a code, and the researchers were provided anon-
ymized clinical information of the linked samples. Hu-
man leukemia cells were obtained from diagnostic bone-
marrow samples (containing at least 70% blasts) of pa-
tients with FLT3-ITD-mutated AML prior to receiving
chemotherapy at Yonsei University Severance Hospital
between 2006 and 2015. For comparative analysis,
leukemia cells were also obtained form FLT3-WT AML
patients with normal karyotype. Normal, CD34 positive
(CD34 (+)) cells were obtained from healthy donors.
Mononuclear cells from bone marrow were isolated by
Ficoll–Hypaque (Sigma-Aldrich, St. Louis, MO, USA)
density gradient centrifugation, and then cryopreserved
without being cultured. All methods were carried out in
accordance with the relevant guidelines and regulations.
Reagents
Stock solutions of reagents were prepared by dissolving
the reagents in dimethyl sulfoxide (DMSO, Sigma-Al-
drich). SBI-0206965, GSK 2606414, and MRT 68921 were
purchased from Selleck Chemicals (Houston, TX, USA).
Bafilomycin A1 and 3-methyladenine (3-MA) were pur-
chased from Sigma-Aldrich. Hydroxychloroquine
(HCQ) was purchased from Myung-in Pharmaceuti-
cals. z-VAD-FMK was obtained from R&D Systems.
Control cells were treated with equal amounts of
DMSO.
Establishment of the pMY-puro-FLT3-ITD stable cell line
A suspension of 2 × 106 U937 cells was transfected with
pMY-puro-FLT3-ITD (5 μg) using program T-20 of the
Amaxa Nucleofector device (Lonza Cologne GmbH,
Cologne, Germany) according to the manufacturer’s in-
structions. Immediately after electroporation, the cells
were resuspended in complete medium and incubated at
37 °C in a humidified atmosphere containing 5% CO2 for
24 h. pMY-puro-FLT3-ITD-transduced U937 cells were
selected on puromycin (2–10 μg/ml) for 2 months.
Apoptosis analysis
Cells were seeded in 12-well plates at a density of 1 ×
105 cells/well. SBI-0206965 and MRT 68921 were added
directly to the culture medium at the desired concentra-
tion. The final concentration of DMSO did not exceed
0.1% (v/v), which is nontoxic to the cells. After treat-
ment with different doses of the ULK1 inhibitors for the
indicated periods, cells were harvested and subjected to
annexin V assays on an LSR Fortessa flow cytometer
(BD Biosciences). The cells were then resuspended in
Annexin V binding buffer, and incubated with Annexin
V-FITC (BD Pharmingen) and propidium iodide (PI),
and stained with anti-CD34-APC (BD Biosciences) for
30 min for the identification of the CD34+ cell fraction.
Data were analyzed using FACSuite software (BD
Biosciences).
Determination of the mitochondrial membrane potential
(MMP)
The MMP was monitored using DiOC6, as described
previously [31]. We used the DePsipher™ Kit, which uses
a unique cationic dye (5,5′6,6′-tetrachloro-1,1′,3,3’tetra-
ethylbenzimidazolylcarbocyanine iodide) to indicate the
loss of MMP. For each condition, 1 × 106 cells were in-
cubated with 1mL of DePsipher™ solution (Trevigen,
Gaithersburg, MD, USA) in a 5% CO2 incubator at 37 °C
for 20 min and then washed with 1 mL of prewarmed 1X
reaction buffer with stabilizer solution prior to analysis
on a LSR Fortessa flow cytometer (488 nm argon laser).
Data were analyzed using FACSuite.
Transfection of green fluorescent protein (GFP)-
microtubule-associated protein 1 light chain 3 (LC3)
A GFP-LC3 construct was generated as described previ-
ously [20]. Briefly, a suspension of 2 × 106 leukemia cells
was transfected with GFP-LC3 cDNA (5 μg) using pro-
gram V-01 of the Amaxa Nucleofector 2b device. Imme-
diately after electroporation, the cells were resuspended
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in complete medium and incubated at 37 °C in a humidi-
fied atmosphere containing 5% CO2 for 24 h. Cells
expressing GFP-tagged LC3 were used to evaluate au-
tophagy induction.
Confocal microscopy
Cells were centrifuged at 800×g onto glass slides, and
coverslips were mounted with aqueous mounting
medium (Dako) with DAPI (Sigma-Aldrich). Fluorescent
signals were analyzed using a Zeiss LSM 700 laser-
scanning confocal microscope (Göttingen, Germany).
The number of LC3 puncta per cell was quantified as
described elsewhere [26]. To estimate the average num-
ber of LC3 puncta per cell in each treatment group, 20
cells were randomly selected, and puncta in each cell
were manually counted. Results are expressed as the
mean of at least three independent experiments.
Transmission electron microscopy (TEM)
TEM was carried out using standard procedures. Briefly,
cells were fixed with 2% glutaraldehyde/paraformalde-
hyde, pelleted, and treated with 1% osmium tetroxide
(Polysciences). The cells were then embedded in pure,
fresh resin. Thin sections were double stained with 6%
uranyl acetate and lead citrate. The sections were ana-
lyzed by TEM (JEM-1011, JEOL, Tokyo, Japan) at 80 kV.
Western blot analysis
Total cell lysates were prepared and analyzed by western
blotting as described previously [32]. The proteins were
recovered in sodium dodecyl sulfate (SDS) buffer, sepa-
rated by SDS-polyacrylamide gel electrophoresis, and
transferred onto a nitrocellulose membrane. The mem-
brane was blotted with appropriate primary and secondary
antibodies. Rabbit polyclonal antibodies against ULK1, p-
ULK1S757, FLT3, p-FLT3, STAT5, p-STAT5, p-MEK, p-
ERK, caspase-9, caspase-3, PARP, AMPKα, p-AMPKαT172,
mTOR, p-mTORS2448, p70S6K, p-p70S6KT389, PERK, and
p-eIF2a were purchased from Cell Signaling Technology
(Danvers, MA, USA). Rabbit polyclonal antibodies against
LC3 and p-ATG13S318 were obtained from Novus Biologi-
cals (Littleton, CO, USA). Mouse anti-p62/SQSTM anti-
bodies were procured from Abnova (Taipei, Taiwan).
Anti-p-PERKT982 antibodies were purchased from Abcam
(Cambridge, UK). Rabbit anti-p-ULK1S555 and mouse
anti-α-tubulin monoclonal antibodies were obtained from
Merck Millipore (Billerica, MA, USA). The secondary
antibodies were coupled to horseradish peroxidase. The
blots were visualized using an enhanced chemilumines-
cence (GE Healthcare Bio-Sciences; RPN2232).
Statistical analysis
Results are expressed as the mean ± standard deviation
(SD) of at least three independent experiments. Means
of two groups were compared using the two-tailed Stu-
dent t test. Statistical analysis was performed using
GraphPad Prism 4.0 (GraphPad Software Inc). P < 0.05
was considered to indicate statistically significant.
Results
Effects of ULK1 inhibitors on apoptosis in FLT3-ITD AML
We assessed the effect of ULK1 inhibitor treatment rela-
tive to that of DMSO as a control, on the induction of
cell death in a panel of leukemic cell lines harboring
FLT3-ITD mutations or not over a 48-h time course.
MRT 68921, an inhibitor of ULK1 and ULK2, effectively
induced apoptosis in the FLT3-ITD cell lines MV4;11
and MOLM-13 in a dose-dependent manner. However,
the extent of apoptosis induced by MRT 68921 in the
FLT3-WT cell lines HL-60 and U937 was significantly
lower than that in the FLT3-ITD cell lines (Fig. 1a). The
ULK1-specific inhibitor SBI-0206965 also induced apop-
tosis more potently in the FLT3-ITD cell lines than in
the FLT3-WT cell lines (Fig. 1b). ULK1 protein levels
were increased in FLT3-ITD cell lines compared with
those in FLT3-WT cell lines (Fig. 1c). After treatment of
the ULK1 inhibitors MRT 68921 and SBI-0206965,
phosphorylation of ULK1 was suppressed. Thus, we
speculated that ULK1 has a significant role in regulating
cell survival in FLT3-ITD AML cells. To confirm that
FLT3-ITD mutation was associated with ULK1 inhibitor-
induced apoptosis, we established FLT3-ITD-inducible
U937 cell lines (U937/FLT3-ITD #12 and #15) and com-
pared ULK1 inhibitor-induced cell death in these cells
with that in parental U937 cells (Additional file 1; Fig. S1).
The U937/FLT3-ITD cell lines were significantly more
sensitive to MRT 68921 (p = 0.052; #12 versus parental
cells, p = 0.0003; #15 versus parental cells) (Fig. 1d) and
SBI-0206965 (p = 0.0105; #12 versus parental cells,
p = 0.0034; #15 versus parental cells) (Fig. 1e), indicating
that the FLT3-ITD mutation is related to ULK1 inhibitor-
induced apoptosis.
ULK1 inhibitor-induced cell death in primary FLT3-ITD
leukemic blasts but not in normal CD34 (+) cells
Next, we assessed the effects of MRT 68921 and SBI-
0206965 on primary leukemic blasts obtained from FLT3-
ITD (+) (n = 7) and FLT3-WT AML patients (n = 6) and
normal CD34 (+) cells obtained from healthy donors for
allogeneic stem cell transplantation (n = 5). As observed in
case of the cell line, ULK1 protein levels were increased in
FLT3-ITD (+) AML patient cells compared with those in
FLT3-WT AML patient cells (Fig. 2a). As shown in Supple-
mentary Table S1 (Additional file 2) and Fig. 2b and c, the
extent of MRT 68921- or SBI-0206965-induced apoptosis
was significantly higher in the primary FLT3-ITD blasts
than in the leukemia cells obtained from FLT3-WT AML
cases (MRT 68921; p = 0.0001, SBI-0206965; p < 0.0001).
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Normal CD34 (+) cells were relatively unaffected by
MRT 68921 (Fig. 2b) or SBI-0206965 (Fig. 2c). These
results suggested that the ULK1 inhibitors specifically
target FLT3-ITD AML cells, cells, but not normal
CD34 (+) cells.
Caspase activation by ULK1 inhibitors
To further analyze the mechanism of ULK1 inhibitor-
induced apoptosis further, PARP cleavage by activated
caspases was investigated by western blot analysis. As
shown in Fig. 3a, MRT 68921 or SBI-0206965 treatment
Fig. 1 ULK1 inhibition promotes apoptosis in FLT3-ITD AML cell lines. a–e FLT3-ITD AML cell lines (MOLM-13, MV4;11), FLT3-WT AML cell lines
(HL60, U937), and FLT3-ITD-inducible U937 cell lines (U937/FLT3-ITD #12, #15) were treated with various concentration of ULK1 inhibitors (MRT
68921; 2.5 μM, SBI-0206965; 5 μM) for 48 h. a, b The fraction of apoptotic cells in FLT3-ITD and FLT3-WT AML cell lines treated with the ULK1
inhibitors was analyzed by flow cytometry based on Annexin-V/PI exclusion. c Cell lysates were subjected to western blotting for ULK1 expression
before and after treatment of the cell lines with the ULK1 inhibitors. α-Tubulin was used as a loading control. d, e The fraction of apoptotic cells
in U937 AML and U937/FLT3-ITD #12, #15 cell lines treated with the ULK1 inhibitors was analyzed by flow cytometry based on
Annexin-V/PI exclusion
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increased the levels of the cleaved caspase-3 and -9, and
PARP proteins in MV4;11 cells. Furthermore, pretreat-
ment with the pan-caspase inhibitor z-VAD-fmk
(20 μM) for 2 h diminished the MRT 68921- (p = 0.0069)
and SBI-0206965-induced cell death (p = 0.009) of MV4;
11 cells (Fig. 3b). These findings indicated that caspase
activation may be partly attributed to ULK1 inhibitor-
induced apoptosis in FLT3-ITD AML cells. MMP dis-
ruption after MRT 68921 or SBI-0206965 treatment was
assessed by measuring the mitochondrial uptake of the
membrane potential-sensitive dye DiOC6 in MV4;11
and U937 cells. When the cells were treated with 2.5 μM
MRT 68921 or 5 μM SBI-0206965 for 48 h, the popula-
tion of the cell population that lost MMP was 64.73 ±
4.31% and 48.1 ± 10.0%, respectively in MV4;11 cells
(Fig. 3c). In contrast, the ULK1 inhibitors did not affect
on the mitochondrial membrane potential or apoptosis
in U937 cells. This suggested that the apoptosis-
inducing mechanism triggered by ULK1 inhibitors oper-
ates in the mitochondria in FLT3-ITD cells.
ULK1 inhibitor activates prosurvival autophagy
The ULK1 inhibitor is known to inhibit the phosphoryl-
ation of ULK1, which regulates autophagy and lysosomal
fusion, thereby blocking autophagy flux [33]. To deter-
mine whether pharmacologic inhibition of ULK1 affects
autophagy pathway in FLT3-ITD AML cells, we evalu-
ated the effects of MRT 68921 on ULK1-downstream
molecules p-ATG13, LC3 conversion, and p62 in MV4–
11 and U937 cells compared with those in the DMSO
Fig. 2 ULK1 inhibition induces selective apoptosis in FLT3-ITD AML patient-derived cells. a Cell lysates were subjected to western blotting for
ULK1 expression before and after treatment of FLT3-ITD mutated (FLT3-ITD AML #0102) and FLT3-WT AML (FLT3-WT AML #0211) patients cells
with the ULK1 inhibitor (MRT 68921; 2.5 μM). α-Tubulin was used as a loading control. b, c Primary leukemic blasts obtained from FLT3-ITD
mutated and FLT3-WT AML patients and normal CD34+ cells obtained from healthy donors were incubated with ULK1 inhibitors (MRT 68921;
2.5 μM, SBI-0206965; 5 μM) for 48 h. The fraction of apoptotic cells in FLT3-ITD AML, FLT3-WT AML patient cells and normal CD34+ cells treated
with the ULK1 inhibitors was analyzed by flow cytometry based on Annexin-V/PI exclusion. NS, not significant
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control. As shown in Fig. 4a, MRT 68921 induced a de-
crease in the phosphorylation of ULK1 and ATG13. The
level of LC3-II increased upon MRT 68921 treatment in
MV4–11 and U937 cells, indicating that autophagy was
induced. As expected, p62 accumulated in MRT 68921-
treated MV4;11 and U937 cells, suggesting that the
ULK1 inhibitor blocked the p62 degradation process ra-
ther than activating autophagic flux. Following treatment
with MRT 68921 or SBI-0206965, TEM revealed an in-
creased number of autophagosomes in MV4–11 and
U937 cells; furthermore, apoptosomes were observed in
MV4;11 cells (Fig. 4b). MRT 68921 and SBI-0206965
treatment led to significant increases (greater than 10-
fold) in the number of GFP-LC3 puncta in MV4;11 cells
(MRT 68921; p < 0.0001, SBI-0206965; p = 0.0001); even
higher increases were observed in U937 cells (MRT
68921; p < 0.0001, SBI-0206965; p < 0.0001) (Fig. 4c).
These results suggest that ULK1 inhibitors induced au-
tophagy in parallel with inhibiting autophagic flux in
AML cells. We next examined the functional roles of
autophagy induced by ULK1 inhibitors in the AML cell
lines. We examined the effects of 3-MA, a type III PI3K
inhibitor that suppresses the early steps of autophagy,
on MRT 68921- or SBI-0206965-induced apoptosis in
MV4;11 and U937 cells. As shown in Fig. 4d, the frac-
tion of apoptotic cells was significantly increased fol-
lowing 3-MA addition in MV4;11 cells (MRT 68921;
p = 0.0009, SBI-0206965; p = 0.0007). These findings in-
dicated that MRT 68921-induced autophagy was mostly
prosurvival.
Fig. 3 Caspase activity upon ULK1 inhibition in FLT3-ITD AML cells. a Cleaved caspase-3 and -9 and PARP levels were examined after treatment
of MV4;11 cells and U937 cells with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 48 h by western blot analysis. α-Tubulin was used
as a loading control. b After pre-treatment with the pan-caspase inhibitor z-VAD-fmk (20 μM), cells were treated with ULK1 inhibitors (MRT 68921;
2.5 μM, SBI-0206965; 5 μM). The fraction of apoptotic cells in MV4;11 cells and U937 cells was analyzed by flow cytometry based on Annexin-V/PI
exclusion. c The MMP was quantified by measuring membrane potential-sensitive dye (DiOC6) intensity in MV4;11 and U937 cells after treatment
of ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM). CTL, control. NS, not significant
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Fig. 4 (See legend on next page.)
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ULK1 inhibition affects FLT3 signaling
To investigate why ULK1 inhibition potentially targets
FLT3-ITD AML cells, we assessed its effect on the FLT3
signaling pathway. MV4–11, MOLM-13, and FLT3-ITD-
inducible U937 cells exhibited FLT3 phosphorylation
and activation of the downstream signaling cascade, as
evidenced by STAT5, MEK, and ERK phosphorylation
(Fig. 5a). Interestingly, MRT 68921 attenuated FLT3
protein expression and suppressed FLT3, STAT5, MEK,
and ERK phosphorylation in MV4–11 cells (Fig. 5b).
The increased FLT3 phosphorylation levels in the U937/
FLT3-ITD cell lines was also suppressed by MRT 68921
in a dose-dependent manner (Fig. 5c). Next, we investi-
gated the mechanism underlying MRT 68921-induced
FLT3 downregulation in MV4–11 cells. Addition of the
proteasome inhibitor MG132 to MRT 68921 delayed the
decrease in FLT3, indicating that ULK1 inhibition accel-
erated proteasomal degradation of FLT3 (Fig. 5d). Con-
focal microscopy revealed that LC3-positive structures
and FLT3 molecules were present at different locations
within the cell after MRT 68921 treatment (Additional
file 1; Fig. S2A), indicating that FLT3 was not degraded
through MRT 68921-induced autophagy. Inhibition of
autophagy with 3-MA increased MRT 68921-induced
FLT3 degradation (Additional file 1; Fig. S2B). These re-
sults indicate that in FLT3-ITD AML cells, MRT 68921
reduced FLT3 expression at the protein level, and au-
tophagy played a role in protecting cells from this effect.
Unfolded protein response (UPR) under ULK1 inhibition
We observed the effects of MRT 68921 on the UPR by
western blotting. MRT 68921 suppressed the phosphor-
ylation of PERK and eIF2α in MV4;11 cells,, but in-
creased the phosphorylated PERK and eIF2α levels in
U937 cells (Additional file 1: Fig. S1A). Phosphorylation
of PERK and eIF2α in MV4;11 cells was augmented in a
dose-dependent manner upon treatment with the PERK-
specific activator tunicamycin (Additional file 1: Fig.
S1B). However, pretreatment with tunicamycin did not
abrogate MRT 68921-induced apoptosis in MV4–11
cells (Additional file 1: Fig. S1C). Suppression of PERK
with the PERK-specific inhibitor GKS 2606414 did not
affect MRT 68921-induced apoptosis in U937 cells
(Additional file 1: Fig. S1D). Thus, MRT 68921 treat-
ment increased apoptosis in FLT3-ITD AML cells, re-
gardless of PERK signaling activation.
Discussion
Increasing evidence suggests that dysregulated autoph-
agy is a hallmark of malignant disorders and plays com-
plex roles in the tumorigenesis and progression of
cancers and their resistance to treatment, in a context-
dependent manner [10, 11, 31]. The diverse functions of
numerous autophagy-related proteins in cancer have
been extensively evaluated [31, 34]. Among them, ULK1
has drawn the most interest because it plays a key role
in autophagy initiation as an only serine/threonine pro-
tein kinase [35, 36]. The findings that high levels of
ULK1 are associated with poor prognosis in several solid
tumors [28, 37] and that ULK1 inhibition can rescue the
phenotype induced by caspase-3 deletion in AML1/ETO
AML cells [38] suggest that ULK1 is a promising new
therapeutic target for cancers.
FLT3-ITD mutations activate the survival pathway in an
oncogene-addicted state. Given the critical role of autoph-
agy in the cell biology of FLT3-ITD AML [39], ULK1 is
likely to play an important role in this AML subtype. The
higher levels of activated ULK1 and its downstream mole-
cules in FLT3-ITD cells observed in our study suggest that
ULK1 is indispensable for survival in FLT3-ITD-mutated
cells and that its selective inhibition may potentially in-
duce cell death. We demonstrated here for the first time
that two ULK1 inhibitors, MRT 68921 and SBI-0206965,
induced caspase-dependent apoptosis preferentially in
FLT3-ITD-mutated leukemia cell lines and primary
leukemic blasts obtained from FLT3-ITD AML patients,
while sparing normal CD34 (+) cells.
MRT 68921-mediated apoptosis in FLT3-ITD cells
was associated with dose-dependent increases in the
cleavage of caspase-3 and -9, and PARP levels. Pretreat-
ment of MV4–11 cells with the pan-caspase inhibitor z-
VAD-FMK notably reduced the levels of cleaved cas-
pases and PARP, indicating that ULK1 inhibitors in-
duced apoptosis in a caspase-dependent manner. The
(See figure on previous page.)
Fig. 4 Autophagy induction by ULK1 inhibitors in AML cells. a After treatment of MV4;11 cells and U937 cells with 2.5 μM of MRT 68921 for 24 h,
cell lysates were subjected to western blotting for p-ULK1, p-ATG13, LC3-I/II and p62. α-Tubulin was used as a loading control. All experiments
were performed at least three times independently. b TEM-based ultrastructural examination of MV4;11 cells and U937 cells treated with ULK1
inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 24 h. The arrowheads and arrows indicate autophagosomes and condensed chromatin,
respectively. Autophagosomes were counted in at least three different visual fields. Data are the mean ± SD. CTL, control. c MV4;11 and U937 cells
were treated with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 24 h and fixed. Cells were stained for LC3B (green) and observed by
confocal microscopy. Representative micrographs demonstrate the characteristic punctuate staining, which indicates autophagosome formation.
Nuclei were stained with DAPI (blue). The arrowheads indicate LC3 puncta. The arrows denote condensed nuclei. LC3 puncta in each cell were
counted in at least three different visual fields. Data are the mean ± SD. d MV4;11 and U937 cells were treated with ULK1 inhibitors (MRT 68921;
MV4;11, 0.5 μM, U937, 2.5 μM, SBI-0206965; 5 μM) in the presence or absence of autophagy inhibitors 3-MA (5 mM). After incubation for 48 h, the
apoptotic fraction was measured by flow cytometry based on Annexin-V/PI exclusion. Data are the mean ± SD
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interaction between ULK1 and caspase-3 was demon-
strated in AML1/ETO leukemia cells [38]. However, the
molecular interplay between ULK1 and activation of
the caspase cascade in FLT3-ITD AML remains to be
elucidated. We found that the ULK1 inhibitor increased
apoptosis by MMP loss with FLT3 degradation in
FLT3/ITDAML cells. Further research is needed to
clarify the mechanism by which FLT3-ITD prevents
mitochondrial apoptosis. Ju, H. Q et al. showed that
FLT3-ITD causes an increase in aerobic glycolysis
through AKT-mediated upregulation of mitochondrial
hexokinase, which regulates the mitochondrial perme-
ability transition pore [40]. Recently, studies in various
FLT3ITD AML models provided evidence that FLT3
Fig. 5 ULK1 inhibition induces FLT3 degradation in FLT3-ITD AML cells. a FLT3-ITD AML cell lines (MOLM-13, MV4;11), U937 cells, and FLT3-ITD-
inducible U937 cell lines (U937/FLT3-ITD #12, #15) were incubated, and cell lysates were subjected to western blotting using antibodies against
FLT3-downstream molecules (FLT3, p-FLT3, STAT5, p-STAT5, p-MEK, p-ERK). α-Tubulin was used as a loading control. b MV4;11 cells were
incubated with 2.5 μM of MRT 68921 for 48 h, and cell lysates were subjected to western blotting using antibodies against the FLT3-downstream
molecules. α-Tubulin was used as a loading control. c Cell lysates were subjected to western blotting for FLT3 expression before and after
treatment of FLT3-ITD-inducible U937 cell lines (U937/FLT3-ITD #12, #15) with the ULK1 inhibitor (MRT 68921; 1, 2.5 μM). α-Tubulin was used as a
loading control. d MV4;11 cell lysates were subjected to western blotting for FLT3 expression after treatment of the cells with ULK1 inhibitor (MRT
68921; 2.5 μM), proteasome inhibitor (MG132; 10 μM), or both for 48 h
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inhibition induces mitochondrial oxidative stress that
determines the triggering of an apoptotic response [41,
42]. Our study suggests that the role of ULK1 in mito-
chondrial membrane potential and mechanisms by
which the ULK1 inhibitor induces mitochondrial apop-
tosis in FLT3/ITD cells requires further analysis.
ULK1 inhibition also induced cell death, albeit to a
lesser degree, in FLT3-WT leukemia cells, necessitating a
clarification of whether the apoptosis-inducing effects of
ULK1 inhibition were primarily due to ULK1 inhibition or
off-target effects thereof. Both MRT 68921 and SBI-
0206965 inhibited ULK1 activity, as demonstrated by the
reduction in phosphorylation of ULK1 downstream mole-
cules ATG13 (Ser318) [43], beclin-1 (Ser14) [25], and
VPS34 (Ser249) [44] as well as ULK1 itself (T180) [24].
Phosphorylation of ATG13 at serine 318 is directly corre-
lated with ULK1 activity [45]. We observed that the extent
of apoptosis was highly correlated with the reduction in
ATG13 phosphorylation in FLT3-ITD cells.
Although MRT68921 and SBI026965 were developed
to inhibit autophagy [29, 46], the action of these ULK1
inhibitors remains unclear. Particularly, the action
spectrum of these ULK1 inhibitors has not been fully
evaluated in cancer cells, including leukemia blasts,
which are considered to have abnormal autophagy regu-
latory mechanism in a context-dependent manner. In
addition, most published data described the autophagy
inhibitory effects of the ULK1 inhibitors in the settings
of induced autophagy, not in the basal conditions. Inter-
estingly, both MRT 68921 and SBI-0206965 activated
LC3-II conversion and GFP-LC3 puncta and autophago-
some formation, which are indicators of autophagy in-
duction. However, these results did not confirm that
autophagic flux was increased. The increase in p62 level
after ULK1 inhibitor treatment indicated that autophagic
flux was blocked by the ULK1 inhibitor. These results
suggest that the ULK1 inhibitors induced autophagic
flux blockage in parallel with autophagy activation.
Gross autophagy revealed offset results for both actions.
Although the ULK1 inhibitor suppressed p62 degrad-
ation, the accumulation of LC3 II, autophagosomes, and
LC3 puncta were lower in MV4;11 cells than in U937
cells, indicating that autophagic flux is greater in MV4;
11 cells. We demonstrated that this activated autophagy
in FLT3/ITD AML cells played a prosurvival role by
enhancing ULK1 inhibitor-induced apoptosis using
the autophagy inhibitor. Reagents conventionally used
for autophagy inhibition have different mechanisms
and action targets. 3-MA inhibits autophagy by block-
ing autophagosome formation, whereas bafilomycin
A1 and HCQ inhibit the late phase of autophagy.
Since the ULK1 inhibitor activated autophagosome
formation, which is the early phase of autophagy, the
apoptosis-inducing effects of an addition of 3-MA,
rather than BafA1 or HCQ, on ULK1 inhibitors were
investigated.
The mechanisms by which ULK1 inhibiors result in
the activation of prosurvival autophagy in FLT3-ITD
cells remain to be investigated. Under stress conditions,
AMPK can inactivate mTORC1 by phosphorylating the
mTOR upstream regulator TSC2 at the Thr1227 and
Ser1354 residues, leading to autophagy activation [47].
The feedback regulatory mechanism between AMPK
and ULK1 remains to be further elucidated. Cheong H
et al. showed that ammonia production due to amino
acid catabolism is responsible for ULK1-independent au-
tophagy [48]. A recent study suggested that the require-
ment for ULK1 in autophagy induction can be bypassed
by an increase in VPS34 kinase activity, caused by inhib-
ition of a newly identified and negative regulatory VPS34
acetylation event [49]. Additional analysis of ULK1-
independent pathways operating in autophagy may sup-
port our findings.
The direct molecular interactions between ULK1 and
the FLT3-ITD-mutated protein are unknown. In this
study, treatment of MV4–11 cells with ULK1 inhibitors
led to decreases in the levels of phospho-FLT3, as well
as p-ERK and p-STAT5, which are associated with FLT3
activation. These findings indicate that ULK1 inhibition
led to the suppression of FLT3 signaling. It has been
shown that autophagy induces the degradation of onco-
genic fusion proteins in AML, leading to cell differenti-
ation and death of leukemic blasts [50, 51]. Furthermore,
the FLT3-ITD-mutated protein is post-translationally
regulated and degraded by autophagy [39]. However, in
this study, we found that FLT3-ITD molecules and
autophagosomes are located at different sites in MV4;11
cells treated with ULK1 inhibitors. This indicates that
ULK1 inhibition-induced autophagy may not be the
mechanism underlying FLT3-ITD degradation. The
addition of the autophagy inhibitor 3-MA to MRT
68921 led to decreases in the levels of p-FLT3; therefore,
autophagy was speculated that play a protective role
against FLT3 degradation in FLT3-ITD AML cells. In
addition, proteasome inhibition partially attenuated
MRT 68921-induced apoptosis, suggesting that protea-
somal degradation of FLT3-ITD contributed to the
ULK1 inhibition-mediated reduction in the levels of acti-
vated FLT3 and its downstream molecules.
The UPR, which involves three major transducers,
PERK, IRE1, and ATF6, occurs in response to intracellu-
lar and extracellular events that perturb protein folding
in the endoplasmic reticulum (ER) [52]. Autophagy and
UPR pathways are interconnected and regulate cellular
responses to apoptotic triggers such as environmental
and genetic stresses in cancer cells [12, 52]. ER stress
(ERS) is thought to activate autophagy via UPR-
mediated transcriptional upregulation of the autophagic
Hwang et al. Journal of Experimental & Clinical Cancer Research           (2020) 39:85 Page 11 of 14
machinery [53]. We evaluated changes in the activation
of the PERK/eIF2α/ATF4 pathway, which is one of the
essential branches of the UPR, after treatment of MV4–
11 cells with the ULK1 inhibitors. PERK, eIF2α, and
ATF4 phosphorylation decreased upon treatment with
MRT 68921, indicating that the ERS pathway is sup-
pressed following ULK1 inhibition. However, when
AML cells were treated with MRT 68921 plus PERK ac-
tivator or inhibitor, there were no significant changes in
apoptosis This indicates that ERS does not play a critical
role in the ULK1 inhibition-mediated regulation of
apoptosis and autophagy in FLT3-ITD cells.
Conclusions
To our knowledge, the present study is the first to dem-
onstrate that ULK1 inhibitors effectively induce
mitochondria-mediated, caspase-dependent apoptosis in
FLT3-ITD-mutated leukemia cell lines and primary
leukemia cells, but not in normal CD34 (+) cells. Para-
doxically, ULK1 inhibitors also induced prosurvival au-
tophagy, as evidenced by the synergistic enhancement of
apoptosis following the addition of autophagy inhibitors.
Further studies are necessary to determine whether
ULK1 inhibition is an effective strategy for overcoming
FLT3-TKI resistance. Owing to its central role in au-
tophagy regulation, druggable nature, and apparent se-
lectivity over other autophagy inhibitors, along with
minimal effect on normal CD34 (+) cells, ULK1 repre-
sents a promising molecular target for FLT3-ITD AML
treatment.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13046-020-01580-4.
Additional file 1: Figure S1. FLT3-ITD expression in FLT3-ITD-inducible
U937 cell lines. Cell lysates were subjected to western blotting for FLT3-
ITD expression of FLT3-ITD-inducible U937 cell lines (U937/FLT3-ITD #10,
#11, #12, #13, #14, #15). GAPDH was used as a loading control. Figure
S2. The effects of 3-MA on ULK1 inhibitor-induced FLT3 degradation in
FLT3-ITD AML cells. (A) MV4;11 cells were treated with 2.5 μM of MRT
68921 for 24 h and fixed. Cells were stained for LC3B (green) and FLT3
(red) and observed by confocal microscopy. Nuclei were stained with
DAPI. (B) MV4;11 cell lysates were subjected to western blotting for FLT3
expression after treatment of the cells with ULK1 inhibitor (MRT 68921;
2.5 μM), autophagy inhibitor (3-MA; 5 mM), or both for 48 h Figure S3.
Unfolded protein response and ULK1 inhibition in FLT3-ITD AML cells. (A)
MV4;11 and U937 cells were incubated with 2.5 μM of MRT 68921 for 24
h, and cell lysates were subjected to western blotting using antibodies
against the indicated molecules (PERK, p-PERK, p-elF2a). α-Tubulin was
used as a loading control. (B) MV4;11 cells were incubated with various
concentrations of the PERK activator tunicamycin for 48 h. (C) The fraction
of apoptotic cells in MV4;11 cells treated with MRT 68921 (0.5, 1, or
2.5 μM) in the presence or absence of tunicamycin (0.1 or 0.125 μg/ml)
was analyzed by flow cytometry based on Annexin-V/PI exclusion. (D)
The fraction of apoptotic cells in U937 cells treated with ULK1 inhibitors
(MRT 68921; 2.5 μM, SBI-0206965; 5 μM) in the presence or absence of the
PERK inhibitor GSK 2606414 (20 μM) was analyzed by flow cytometry
based on Annexin-V/PI exclusion. Figure S4. Densitometry analyses on
the entire western blot experiments. (A-C) Figure S5. Densitometry ana-
lyses on the entire western blot experiments. (D-H)
Additional file 2: Table S1. Effects of ULK1 inhibitors on phenotypes
and apoptosis of primary acute myeloid leukemia FLT3 cells
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